Due to technical reasons, Nanologica AB moves the year-end report for 2024 to Friday, February 14. The year-end report will be published on the company’s website at approximately 08.10. See press release
Nanologica has received yet another order for the company’s silica-based purification media NLAB Saga® from the Chinese pharmaceutical manufacturer Chengdu Shengnuo Biopharm Co. (“Shengnuo”). The order is worth approximately SEK 8.5 million and the customer uses Nanologica’s purification media in the production of a GLP-1 analogue. Since June 2024, Shengnuo has placed five orders of NLAB Saga® with a total value of approximately SEK 18 million. ”The Chinese market is very interesting for us and
Nanaologica Receives Order on NLAB Saga® Valued at approx. SEK 1,9 Million from Returning Customer in China Nanologica has received another order for the company’s silica-based purification media NLAB Saga® from a returning customer in China. This is the fourth order since June from this customer who uses NLAB Saga® in the production of a GLP-1 analogue. “The fact that this customer is now placing another order for NLAB Saga® confirms once again that our
FINANCIAL SUMMARY Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period to SEK 7,822 thousand (1,368) Operating loss for the quarter amounted to SEK -22,203 thousand (-10,292) and for the nine-month period to SEK -47,365 thousand (-34,324) Loss before tax for the quarter amounted to SEK -23,701 thousand (-11,554) and for the nine-month period to SEK -51,561 thousand (-38,318) Earnings per share before and after dilution were
Nanologica AB (publ) (“Nanologica” or the “Company”) today announces the outcome of the Company’s rights issue of approximately SEK 99.4 million (the “Rights Issue”), for which the subscription period ended on October 14, 2024. The Rights Issue concerns so-called units, consisting of four shares and one free of charge warrant of series TO 2024/2025 (“Unit”). The Rights Issue has been subscribed to approximately 87.0 percent with and without the support of unit rights, of which
Nanologica has received a supplementary order for the company’s silica-based purification media NLAB Saga® from the customer in China who at the end of September placed an order for NLAB Saga® at a value of approximately SEK 3.7 million. The value of this supplementary order amounts to approximately SEK 1.9 million. The customer is a pharmaceutical manufacturer that primarily produces peptides including GLP-1 analogues. In June this year, they placed a first order for NLAB
